Trial Profile
A Phase 2, Multicenter, Three-part Study to Establish the Dosage, Safety and Antiviral Activity of Combination Therapy With Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects With HIV-1 Infection
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Labuvirtide (Primary) ; Teropavimab (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms ABL
- Sponsors Frontier Biotechnologies
- 28 Sep 2021 Planned End Date changed from 1 Oct 2020 to 1 Dec 2022.
- 28 Sep 2021 Planned primary completion date changed from 1 Apr 2020 to 1 Dec 2022.
- 28 Jan 2019 Status changed from not yet recruiting to recruiting.